Actively Recruiting
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
Led by Tulane University · Updated on 2026-05-19
2000
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
Sponsors
T
Tulane University
Lead Sponsor
C
Centers for Disease Control and Prevention
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are conducting an observational study to better understand how SARS-CoV-2 infections develop and affect people over time, including those with other respiratory viruses. The study aims to track virus shedding, immune responses, and long-term health effects known as post-acute sequelae of SARS-CoV-2 (PASC). This includes monitoring antibody responses and identifying factors that influence disease severity and recovery. The research also seeks to help improve screening, treatment, and prevention strategies for COVID-19 and similar infections. Participants include those recently diagnosed with COVID-19 and other respiratory viruses, as well as individuals who may have been exposed and developed antibodies without confirmed diagnosis. The study collects blood and virus samples to analyze viral genetics, immune responses, and inflammatory markers. Two groups are involved: one with active or recent infections, and another with past infections or possible exposure. Consent is obtained verbally or in writing as appropriate. Throughout participation, individuals provide samples and clinical information at multiple time points to assess symptoms and outcomes up to two years after infection. The study measures include severity of COVID-19 cases and onset of post-COVID symptoms at intervals from 3 months to 24 months. Data collected will help identify predictors of long-term effects and support future treatment development. Participants may be monitored for changes in health status and immune responses during the follow-up period.
CONDITIONS
Brief Title
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Positive diagnostic test for COVID-19, influenza A or B, non COVID-19 coronavirus, parainfluenza virus, rhinovirus, adenovirus, or metapneumovirus
- Patient or legally authorized representative has provided verbal consent or signed informed consent (including parental permission and assent if appropriate)
- Positive COVID-19 test more than 14 days prior, or potential exposure with antibodies against COVID-19 (for Population 2)
You will not qualify if you...
- Under 6 months old
- Anemia with hemoglobin less than 7
- Platelet count below 80
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or by telephone) for consent and eligibility assessment
Duration - Up to 2 years
Participants provide blood and other samples to help understand COVID-19 infection, immune response, and potential treatments.
1 to 2 visits depending on participant group and exposure history
Duration - Up to 2 years
Participants are monitored to determine long-term health impacts and post-COVID symptoms over time.
Periodic visits at 3, 6, 9, 12, 15, 18, 21, and 24 months
Trial Site Locations
Total: 2 locations
1
Tulane University Medical Center
New Orleans, Louisiana, United States, 70112
Actively Recruiting
2
University Medical Center New Orleans
New Orleans, Louisiana, United States, 70112
Actively Recruiting
Research Team
D
Dahlene Fusco, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here